financetom
Business
financetom
/
Business
/
Ford accuses law firms of fraudulent overbilling, including a 57-1/2 hour workday
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ford accuses law firms of fraudulent overbilling, including a 57-1/2 hour workday
May 26, 2025 12:04 PM

(Reuters) - Ford sued several California lawyers and law firms on Wednesday, accusing them of fraudulently inflating their legal fees under that state's Lemon Law, including one instance where a lawyer allegedly billed 57-1/2 hours in one day.

In a complaint filed in Los Angeles federal court against nine defendants, Ford called the alleged improper billings a "magical mystery tour" of bogus work and time entries, spread across thousands of cases against several automakers so they would go undetected.

Ford said the law firm Knight Law Group anchored the scheme, regularly bringing in other law firms to overstaff cases, sometimes with 10 to 15 lawyers.

The Dearborn, Michigan-based automaker said it lost at least $100 million from the scheme over five years. It is seeking at least $300 million in damages for alleged violations of the federal anti-racketeering law known as RICO.

Requests for comment on behalf of the defendants were not immediately returned.

The complaint identified "numerous" alleged instances of lawyers billing more than 24 hours in a single day.

Ford said the 57-1/2 hours that Knight partner Amy Morse allegedly billed on November 30, 2016 included 12.9 hours on "requests for admission," where parties ask opponents to admit that facts are true or documents are authentic.

The automaker said another lawyer allegedly billed 29 hours to prepare for, travel to and attend two trials on the same day in Los Angeles and near San Francisco, about 400 miles apart.

California's Lemon Law, the Song-Beverly Consumer Warranty Act, lets lawyers collect legal fees based on reasonably incurred time spent representing vehicle owners.

The case is Ford Motor Co ( F ) v Knight Law Group LLP et al, U.S. District Court, Central District of California, No. 25-04550.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
OpenAI to cut access to tools for developers in China and other regions, Chinese state media says
OpenAI to cut access to tools for developers in China and other regions, Chinese state media says
Jun 25, 2024
BEIJING, June 25 (Reuters) - ChatGPT maker OpenAI is planning to block access to technology used to build artificial intelligence products for entities in China and some other countries, a Chinese state-owned newspaper reported on Tuesday. ChatGPT is not available in mainland China but many Chinese startups have been able to access OpenAI's application programming interface (API) platform and use...
Halozyme Therapeutics Says Roche's OCREVUS SC With ENHANZE Gets European Commission Approval
Halozyme Therapeutics Says Roche's OCREVUS SC With ENHANZE Gets European Commission Approval
Jun 25, 2024
04:41 AM EDT, 06/25/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said Tuesday that Roche received European Commission marketing authorization of OCREVUS SC co-formulated with ENHANZE, Halozyme's proprietary recombinant human hyaluronidase enzyme, for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis. OCREVUS SC is a 10-minute injection that maintains the same twice-yearly schedule as the approved...
--Nvidia Shares Attempt Rebound Premarket Tuesday After Closing 6.7% Lower Monday
--Nvidia Shares Attempt Rebound Premarket Tuesday After Closing 6.7% Lower Monday
Jun 25, 2024
04:47 AM EDT, 06/25/2024 (MT Newswires) -- Price: 116.57, Change: +0.93, Percent Change: +0.84 ...
Novo Nordisk's Wegovy weight-loss drug approved in China
Novo Nordisk's Wegovy weight-loss drug approved in China
Jun 25, 2024
SHANGHAI (Reuters) -Novo Nordisk said on Tuesday its popular weight-loss drug Wegovy has been approved in China, paving the way for sales in the world's second-largest economy. Novo said in March that it would initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug. The company did not immediately respond to a Reuters request for comment on...
Copyright 2023-2025 - www.financetom.com All Rights Reserved